Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 20, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on...
-
Dec 17, 2012Company Begins Evaluation of its Next Generation Pacing Leads
The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial...
-
Dec 12, 2012Close the Gap Initiative Urges Fans to Learn Their Risk Factors for Heart Disease and Take Responsibility for Their Heart Health
The Boston Scientific Corporation (NYSE: BSX) health equity initiative, Close the Gap, will once again be the title sponsor of the Crossroads Classic,...
-
Dec 7, 2012World's First and Only System with 32 Contacts and 32 Dedicated Power Sources is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval and has begun the European market launch of the Precision Spectra™ Spinal...
-
Dec 4, 2012Study to Compare Clinical Outcomes of Self-Expanding Metal Stents (SEMS) Versus Plastic Stents for the Treatment of Biliary Strictures Caused by Chronic Pancreatitis
The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX) study comparing the WallFlex® Biliary RX Fully Covered...
-
Nov 30, 2012
The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the...
-
Nov 20, 2012Devices Projected to Have up to Twice the Longevity of Comparable Products
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™,...
-
Nov 8, 2012Company to Consolidate Natick, Mass. Headquarters into Existing Marlborough Site; Facility Expansion to Create Collaborative Campus Setting; Consolidation Expected to be Completed by Mid-Summer 2014
Natick, Mass. (November 8, 2012) – Boston Scientific Corporation (NYSE:BSX) announces it will consolidate its Natick, Mass. global headquarters into its Marlborough, Mass. location, where a new...
-
Nov 8, 2012Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology
Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive...
-
Nov 6, 2012MADIT-RIT Clinical Trial Study Results Published Today in the New England Journal of Medicine
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic...
-
Nov 1, 2012Appointment Completes Company's CEO Transition Plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman
In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX) today named Michael F....
-
Oct 31, 2012This Innovative Bioabsorbable Coating is the First to Complete Absorption Shortly after Drug Elution Ends at Three Months
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 24, 2012
Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS...
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the...
-
Oct 23, 2012Twelve-Month Data Presented at TCT 2012 Support Safety and Efficacy of Epic Stent in Iliac Stenting
Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and...
-
Oct 23, 2012Results Presented on Cost Effectiveness and Clinical Benefits for Older Patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System Feasibility Trial Results Reviewed
Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.16 for the third quarter ended...
-
Oct 10, 2012REPRISE II Study Results Expected to Support CE Mark and Other Regulatory Filings
Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™...
-
Oct 9, 2012Victory™ guidewires are designed to facilitate crossing of resistant lesions
Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing...
-
Oct 8, 2012Pending Addition of Next Generation Mapping and Navigation System Would Expand Company Portfolio into Complex Electrophysiology Procedures
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of...
-
Oct 8, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its third-quarter 2012 financial results conference call on Thursday, October 18th, at 8:00 a.m....
-
Oct 3, 2012These Disorders Affect Nearly 30 Million American Women; New Research Shows High Prevalence of Patients Not Understanding Their Treatment Options
Boston Scientific Corporation (NYSE: BSX) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed to...
-
Oct 2, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
To view the multimedia assets associated with this release, please click:...
-
Sep 28, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's...